|Activity Title||Current Therapies for Overactive Bladder|
|Accreditation Type||AMA PRA Category 1 Credit™|
|Release Date||December 21, 2012|
|Expiration Date||December 20, 2013|
|Estimated Time to Complete Activity||60 minutes|
Upon completion of the activity, participants should be able to:
- Identify current and emerging therapies for treatment of overactive bladder and their role in improving patient adherence, persistence, and outcomes
Karen L. Noblett, MD
Professor, Department of Obstetrics and Gynecology
Director, Division of Urogynecology and Female Pelvic Medicine and Reconstructive Surgery
University of California, Irvine
Peter L. Rosenblatt, MD
Assistant Professor, Department of Obstetrics and Gynecology
Harvard Medical School
Director of Urogynecology and Reconstructive Pelvic Surgery
Mount Auburn Hospital
This site is best viewed using Internet Explorer 8.0 or higher, or Firefox 4.0 or higher. For interactive content, a broadband connection is required. For all CME/CE activities featuring audio you must have a sound card and speakers.
Our interactive activities may require the Adobe Flash Player (available from the Adobe Web site) and Adobe Shockwave Player (available from the Adobe Web site). Both browser plug-ins are free.
This activity is presented by AUGS.
This activity is sponsored by The France Foundation.
This activity is intended for health care providers involved in the management of patients with overactive bladder, including obstetricians/gynecologists, urologists, primary care providers, nurse practitioners, and other allied health care providers.
STATEMENT OF NEED
It is well known that 33 million people in the United States suffer from overactive bladder (OAB), and direct and indirect health care costs associated with the disease have been estimated at $12 billion. In addition to the societal burden of the disease, it also significantly affects the patient’s quality of life. Unfortunately, due to many reasons, including embarrassment and or equating symptoms to the normal part of aging, those suffering from OAB hesitate to discuss the condition with their doctor. Even when diagnosis of OAB occurs, a great number of patients remain untreated. Finally when treatment occurs, it has been shown that discontinuation rates have been as high as 70–90% within the first year of therapy for those patients on various OAB medications.
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The France Foundation designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME-accredited provider.
RESOLUTION OF CONFLICTS OF INTEREST
In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
The following faculty have indicated they have relationships with industry to disclose relative to the content of this CME activity:
- Karen Noblett, MD, has received grant/research support from the AUGS Foundation and Boston Scientific. She has served as a consultant for Allergan, Boston Scientific, and Medtronic. Dr. Noblett has received honoraria from Astellas
- Peter L. Rosenblatt, MD, has received grant/research support from Boston Scientific and Coloplast. He has served as a consultant for AMS, Boston Scientific, and Ethicon. Dr. Rosenblatt has received other financial or material support from AMS, Cook, and Cooper Surgical
UNAPPROVED USE DISCLOSURE
The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Astellas.
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Astellas assume no liability for the information herein.
Copyright © 2012 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME or ACPE.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or email@example.com.